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1. Introduction 
Nuclear factor-κB (NF-κB) is a nuclear transcription factor first recognized in 1986 by Sen 
and Baltimore. Its name derives from the fact that it was first diagnosed in the nuclei of B 
cells [1- 3] bound to an enhancer element of the immunoglobulin kappa light chain gene 
[4]. At that time, NF-κB was primarily thought to be a B-cell–specific transcription factor, 
but it was afterward found to be present in every cell type [5]. NF-κB has been implicated 
in the regulation of host inflammatory [6-8] and immune responses [9-11], cell adhesion 
[12], developmental signals [13], cell proliferation, differentiation [14, 15] and in 
defending cells from apoptosis [16, 17]. In addition, it plays important roles in cellular 
growth properties by encoding cytokines, chemokines and receptors required for 
neutrophil adhesion and migration, thus increasing the expression of specific cellular 
genes [18].  
Physical and chemical damage to the lung causes an inflammatory response, thus defending 
the lung against the causative agents. Inflammation initiates a series of cellular procedures 
which lead to healing the injury; however, if resolving the inflammatory response is 
inefficient, the result is a chronic situation. Numerous pathophysiologic conditions and 
inhaled air pollutants are identified as generating stable stimulation of phagocytic cells, 
leading to the amplification of proinflammatory cytokines, and mediating chronic 
inflammation in the lung [19]. 
Many studies have reported the role of NF-kB in inflammation and proven the association of 
NF-κB with human inflammatory lung diseases. The point of this short review is to 
summarize what is known about the molecular biology and activation pathway of NF-κB 
and to highlight the role of NF-κB in the pathogenesis of inflammatory lung disease, as well 
as in asthma, COPD, ARDS, and cystic fibrosis. 
1.1 Molecular pathway of NF-κB and its activation 
In mammals, the NF-κB highly conserved protein family is composed of five members, 
p50 (precursor protein: p105), p52 (precursor protein: p100) [20, 21], p65 (RelA), c-Rel, and 
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RelB [22]; these are encoded by NFKB1, NFKB2, RELA, REL, and RELB, respectively [23], 
which share the so-called N-terminal Rel homology domain (RHD), responsible for DNA 
binding and homo- and heterodimerization [24, 25]. Various combinations of dimeric 
complexes bind to κB sites within the DNA, where they directly regulate transcription of 
target genes [26]. The major form of NF-κB in cells is a p50/RelA heterodimer [27]. The 
diverse Rel/NF-κB proteins exhibit different abilities to shape dimers [4], dissimilar 
preferences for different κB sites [28, 29], and distinct abilities to interact with inhibitory 
subunits known as IκBs. Because different Rel/NF-κB complexes can be induced in 
different types of cells and via different signals, they can cooperate in diverse ways with 
other regulatory proteins and transcription factors to control the expression of particular 
gene sets [30].  
In their unstimulated state, NF-κB dimers can be found in the cytoplasm of a large variety of 
cells as an inactive complex controlled by their interaction with the κB family of inhibitor 
proteins (IκB) [31, 32]. They block NF-κB nuclear localization sequences and thus cause its 
cytoplasmic retention [33, 34]. Numerous IκBs have been identified; there are three typical 
IκB proteins, IκBǂ [35], IκBǃ [36] and IκBǆ [37], and two atypical IκB proteins, Bcl-3 [38] and 
IκBǇ, which act in a different way [39]. The precursor proteins p100 (NFKB2) and p105 
(NFKB1) also act as inhibitory molecules [40].  
Most mediators that activate NF-κB are involved in the phosphorylation-induced 
degradation of IκB. Phosphorylation of IκB by the multisubunit IκB kinase (IKK) complex in 
N-terminal regulatory domain at two critical serine residues (S32 and S36) [41] results in the 
ubiquitination and subsequent degradation of IκB by the 26S proteasome [42-44]. Free NF-
κB dimmers translocate into the nucleus, where they bind to specific promoters and affect 
gene transcription [45, 46]. 
A variety of upstream extracellular signals, including tumor necrosis factor alpha (TNF-ǂ) 
[47-50], lipopolysaccharide [51], virus infection (human T-cell leukemia virus, HIV1) [52- 
54], ionizing radiation [55], interleukins such as IL-1ǃ [48], epidermal growth factor (EGF) 
[3], mitogens [56], bacteria [52], reactive oxygen species (ROS) [48], environmental hazards 
such as cigarette smoke [57], and physical and chemical stresses [58], activate the IKK 
complexes, which are comprised of three subunits: IKKǂ, IKKǃ, and IKKǄ/ NEMO. IKKǂ 
and IKKǃ are catalytic subunits, and IKKǄ functions as a regulatory subunit [59-61].  
Numerous genes associated with the inflammatory process include proinflammatory 
cytokines (such as TNF-ǂ), cell adhesion molecules (such as intercellular adhesion molecule 1) 
[62, 63], or assumed NF-κB binding sites in their promoters that can amplify the 
inflammatory response and enhance the time of chronic inflammation. NF-κB also induces 
the expression of enzymes whose proteins have a connection to the pathogenesis of the 
inflammatory procedure, such as inducible cyclooxygenase (COX-2) [18], which generates 
prostanoids, and the inducible type of nitric oxide synthase (iNOS), which manufactures 
nitric oxide (NO) [64, 65]. These facts emphasize the significance of NF-κB as a regulator of 
inflammatory gene activation and indicate it as a predominant choice for targeted 
inactivation. In fact, diverse techniques intended to improve or suppress the inflammatory 
process related to determined pathologies have already been directed at obstructing the 
biological actions of NF-κB (Figure 1). 
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Fig. 1. Schematic representation of NF-κB  activation in inflammatory disease. A variety of 
upstream extracellular signals activate the IKK complexes, which are comprised of 3 
subunits: IKKǂ, IKKǃ, and IKKǄ. Phosphorylation of IκB by the IKK complex in the N-
terminal regulatory domain at two critical serine residues results in the ubiquitination and 
subsequent degradation of IκB by proteasome. Free NF-κB dimmers translocate into the 
nucleus, where they bind to specific promoters and affect gene transcription of such 
molecules as proinflammatory cytokines, cell adhesion molecules, COX-2, and iNOS. Some 
drugs and agents are able to suppress NF-κB activation via different pathways. Aspirin and 
sodium salicylate block IkB phosphorylation and degradation. Sulindac, Parthenolide, 
Aspirin inhibit activation of the NF-kB pathway by suppressing IKK activity and MRS2481 
inhibit TNF-ǂ.  
1.2 Asthma 
Asthma is a chronic inflammatory disease [65, 66] of the airway accompanied by reversible 
bronchial hyperreactivity. Increased numbers of Th2 lymphocytes [67] and eosinophils in 
the airway can cause chronic inflammatory response, leading to asthma [68, 69]. In addition 
to the existence of inflammatory cells in the airway, these patients expose changing levels in 
structure of airway, termed remodeling [69, 70]. As cited above, NF-κB is one of the most 
important transcription factors involved in the expression of wide groups of inflammatory 
proteins, including cytokines, adhesion molecules, and enzymes, which themselves are 
implicated in the pathogenesis of asthma [71]. Translocation of NF-κB and its binding 
activity increases in airway specimens from asthmatics, in airway epithelial cells obtained 
from bronchial mucosal biopsies, and in alveolar macrophages extracted from sputum. 
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Results show that the agents that are coordinate with deterioration of asthma generally 
activate NF-κB. Viral infections, allergens [72], and ozone, all of which can cause activation 
of NF-κB, are related to aggravation of asthma [73]. 
Viral infections of the upper respiratory airway might intensify asthma by activation of NF-
κB. In cell cultures of bronchial epithelial cells, rhinovirus causes induction of oxidative 
stress and NF-κB activation and increases expression of IL-8, which can in turn participate in 
neutrophil recruitment into the upper respiratory tract. Respiratory syncytial virus (RSV) 
has been involved in stimulation of NF-kB and consequent expression of IL-8 and IL-1 in 
human type II–like alveolar epithelial cells (A549 cells). Thus NF-κB seems to be activated 
during replication of RSV (Table 1)[73].  
In vitro research has revealed that allergens activate NF-κB in bronchial epithelial cells of 
asthmatic patients. For example, exposure to aerosolized ovalbumin causes profound 
activation of NF-κB  and transcription of inducible nitric oxide synthase in the respiratory 
tract of sensitized Brown Norway rats [73]. Mice lacking the NF-κB subunits p50 or c-Rel 
exhibit less airway inflammation in response to an antigen challenge, signifying the 
fundamental role of NF-κB in allergic respiratory disease [68]. 
Furthermore, activation of NF-κB has also been illustrated in animal models of allergic 
airway inflammation in airway epithelium. However, inhibition of NF-κB activation in 
airways did not ameliorate airway hyperresponsiveness, a key characteristic of asthma. 
These findings reveal that NF-κB activation in airway epithelium is essential to the airways 
in response to allergen activity via recruitment of inflammatory cells but also exhibits a 
different segregation between hyperresponsiveness and airway inflammation [68]. 
Airway irritants such as ozone may also exacerbate asthma symptoms and trigger 
inflammation through NF-κB activation. Exposure of A549 cells to ozone affects activation 
of NF-κB and transcription of IL-8. Another study revealed that rats exposed to ozone 
subsequently show time- and dose-dependent activation of NF-κB and modulate 
penetration of neutrophils and monocytes into lavageable airspace via expression of CXC 
and CC chemokines, respectively [73]. 
Cre/lox molecular techniques have been examined whether inhibiting NF-κB expression 
only in airway epithelial cells in a mouse model would diminish levels of airway 
remodeling. In selective airway epithelial cells frominhibitor of κB kinase ǃ (Ikkǃ) knockout 
mice, peribronchial fibrosis had considerably reduced levels of TGF-ǃ in BAL, and numbers 
of cells had positive peribronchial TGF-ǃ1. Airway epithelial Ikk-ǃ ablation also leads to 
reduction in levels of mucus and eosinophils in the airway [69].  
Reduction in expressions of NF- κB-regulated chemokines such as eotaxin-1 and Th2 cells 
can diminish airway inflammatory response in the airway as well. These findings support 
the key role of NF-κB pathway the in bronchial epithelium and its significance in the process 
of remodeling [69]. 
As cited above, expression of some cytokines and adhesion molecules as a result of NF-κB 
activation exacerbates inflammation in airway cells. For example, tumor necrosis factor 
alpha (TNF-ǂ) is a cytokine produced by macrophages and associated with inflammation. It 
increases the expression of adhesion molecules for recruitment of immune cells to damaged 
tissue. TNF-ǂ may also be involved in expression of intercellular adhesion molecule 1 
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(ICAM-1). It has been illustrated that epithelial upregulation of ICAM-1, which has an 
important role in cellinteraction, exists in asthmatics. Active bronchial asthma is matched by 
an amplified level of soluble ICAM-1 in serum and thereby is associated with the 
pathogenesis of asthma. When rhinoviruses activate NF-κB, it amplifies the gene expression 
ofICAM-1 in bronchial epithelial cells, because rhinovirus utilizes ICAM-1 as a cellular 
receptor [73]. 
1.3 Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow 
obstruction which is irreversible. COPD is a complex of two chronic lung diseases: chronic 
bronchitis and emphysema both caused mainly by a familiar irritant, cigarettes [74]. The 
inflammatory response in smokers’ lungs is not fully understood [75]. One theory is that 
cigarette smoke disturbs the oxidant/antioxidant balance by induction of oxidative stress, 
which stimulates activation of redox-sensitive transcription factors such as NF-κB. 
Transcription factors, including NF-κB (Table 1) and activator protein 1 (AP-1), have a key 
role through gene transcription of wide range of inflammatory cytokines that cause airway 
inflammation, including TNF-ǂ interleukin (IL)-8, and interleukin (IL)-6 [41, 76]. As well, 
NF-κB has been demonstrated to be a mediator of cigarette smoke effects on gene 
transcription in various cell types. Its activated dimer has been revealed to be induced in 
bronchial biopsies of smokers [77]. 
Previous studies have reported that cigarette smoke increases DNA damage in lung 
fibroblasts and human bronchial epithelial cells; however, this does not lead to necrosis or 
apoptosis. Lung fibroblasts and human bronchial epithelial cells are capable of repairing 
DNA damage and forming colonies after sub-culturing in normal medium. Cigarette-
smoke-induced DNA damage is involved in modulating cell survival or apoptosis via 
numerous signaling pathways. It has been elucidated that NF-κB plays a significant role in 
mediating cell survival [78]. 
Transcription of genes is not only dependent upon transcription factor bindings; it is also 
related to the alteration of core histone proteins which adjust the availability of the genome 
to cofactors and nuclear factors. Octamers are composed of two copies of each histone core 
protein, H2A, H2B, H3, and H4, and DNA covers them. Post-translational modification of 
N-terminal side chains of each histone cause conformational changes via phosphorylation, 
methylation and acetylation[76].  
Histone acetyltransferases (HATs) acetylate lysine residues in histones, neutralize their 
positive charge, and lead to chromatin relaxation, increasing binding of transcription factors 
and RNA polymerase II, which unwinds DNA and increases gene amplification [76].  
The imbalance of acetylation/deacetylation and increase in acetylation might cause 
transcription of proinflammatory genes mediated by NF-κB and therefore initiate chronic 
inflammation. Consequently, the imbalance of histone acetylation/deacetylation may have a 
role in the inflammatory response in “susceptible” smokers who progress toCOPD [76]. 
When NF-κB translocates into the nucleus and acetylates histone H4, the sequence leads to 
DNA relaxation and transcriptional accessibility. Research has shown that smoking 
cessation in patients suffering from COPD causes increased histone H3 acetylation, 
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illustrating that the stability of the inflammation in the lungs in COPD after smoking 
cessation may be regulated by H3 acetylation. As cited above, this study shows that 
cigarette smoking affects chromatin remodeling in the lungs [76]. Smoking has been found 
to reduce expression of IκB protein dramatically and thus affects regulation of NF-κB. 
Unexpectedly, in ex-smokers with COPD, a notable depletion of IκBǂ has been detected. 
Nevertheless, the NF-κB DNA binding in these patients was similar to that in nonsmokers 
[76]. Other investigations confirm the enhanced activation of NF-κB in cigarette smoke. 
Cigarette-smoke-exposed Guinea pigs increase expression of IL-8 in response to NF-κB 
activation. Furthermore, studies of smokers and number of pack-years reveal a positive 
correlation with NF-κB activation. Smokers with COPD and currently healthy smokers both 
increase DNA binding activity of NF-κB [76]. NF-κB expression and its translocation in lung 
tissue and sputum increase in COPD patients in comparison with non-smoking controls, 
and this seems to be related to exacerbation [79]. 
Caramori and coworkers investigated p65 expression in leucocytes extracted from sputum 
patients with exacerbated COPD and revealed p65 transcription in macrophages but not in 
neutrophils [80]. 
Even though an enhanced proinflammatory molecule whose expression is vitally dependent 
on NF-κB activation has been formerly described in COPD, the role of NF-κB activation has 
not been determined. We hypothesize that, through COPD exacerbations, initiation factors 
including viral and bacterial infections could activate NF-κB, generate cytokines and 
chemokines, and lead to inflammatory cell penetration of the airways. Sputum 
immunocytochemistry methods have evidenced activation of p65 in alveolar macrophages 
through COPD exacerbations [80]. 
As a sign of oxidative stress activation, Di Stefano and colleagues demonstrated increases in 
activation of NF-κB in segmental and subsegmental bronchial biopsies in COPD subjects 
and healthy smokers accompanied by enhanced lipid peroxidation products. They reported 
increased localization of p65 and its immunoreactivity in bronchial epithelium but not in 
submucosa. Nevertheless, they could not diagnose any difference between healthy smokers 
and COPD smoking subjects [81]. Similarly, Yagi and coworkers investigated IκBǂ 
expression by an immunostaining method to measure NF-κB activation indirectly in airway 
epithelial cells. They revealed increased levels of phosphorylated IκBǂ in both ex-smokers 
with COPD and subjects without COPD. Phosphorylated IκBǂ underwent degradation and 
freed NF-κB to bind to enhancers of related genes [76]. 
Inflammatory molecules in COPD cause increased neutrophils and inflammatory agents in 
the airways and bronchial tissue of patients [79]. Mishra and colleagues reported that NF-κB 
can be inhibited independently from IκBǂ and may be inhibited via a peroxisome 
proliferator-activated receptor ǂ (PPAR-ǂ). The interaction of PPARǂ with the p65 and c-Jun 
subunits of NF-κB and AP-1, respectively, may block their activation, suppressing 
expression of cytokines such as IL-6 [76].  
1.4 Cystic fibrosis 
Cystic fibrosis (CF) is a chronic inflammatory airway disease caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene. Lung disease in CF 
expresses a profoundly proinflammatory phenotype related to increased constitutive 
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viscosity of respiratory secretions and chronic lung infection by Pseudomonas aeruginosa and 
other bacterial species, resulting in considerable morbidity in cystic fibrosis subjects 
followed by the lack of innate immune responses [73].  
Pseudomonas aeruginosa supposedly causes activation of NF-κB and may play an important role 
in overproduction of mucin caused by the increase in MUC2 mucin transcription (Table 1) 
[73]. Even though there is not enough data in vivo, enhanced activation of NF-κB and 
amplification of IL-8 can be observed in bronchial epithelial cells that display CFTR 
mutations (IB3 cells) in comparison with normal bronchial epithelial cells line (C38 cells). To 
decrease sputum viscosity in CF patients, inhibition of NF-κB activation might be a useful 
procedure for decreasing airway inflammation and improve lung function [82]. These 
findings show that CFTR mutations are related to modification of NF-κB levels and airway 
inflammation [73]. Another research revealed that, in either wild-type (WT) or mutant 
(CFTR) isogenic bronchial epithelial cell lines infected by Pseudomonas aeruginosa, 
transcriptional changes occur in cytokine production. For example, NF-κB activates 
transcription of four -regulated cytokines include ICAM-1, CXCL1, IL-8 and IL-6, but 
protein expression in both cell lines involves only enhancement of IL-6 and IL-8 expressions. 
Inhibition of NF-κB prior to countering t Pseudomonas aeruginosa revealed different levels of 
dependence on NF-κB for expression of the cytokines [83]. 
T. Joseph  and colleagues demonstrated that in vitro activation of NF-κB in human airway 
epithelial cells isolated from CF (DeltaF508/DeltaF508) and non-CF (NCF) patients when 
infected by Pseudomonas aeruginosa elevated nuclear levels of IkBǂ in CF cells, although this 
increase was transient. They also showed increased baseline translocation of NF-κB to nuclei 
in primary CF epithelial cell cultures; following Pseudomonas aeruginosa infection, activation 
of IκBǂ might suppress that of NF-κB [84].  
In a systematic search for drugs for therapeutic treatment that may be utilized for inhibition 
of IL-8 secretion from these cells, a series of amphiphilic pyridinium salts was examined. 
The most effective of these salts is a (R)-1- phenylpropionic acid ester known as MRS2481. 
For optimal activity, it has been demonstrated that the ester ought to be joined to the 
pyridinium derivative by an eight-carbon chain. MRS2481 seems to be able to suppress 
signaling of the NF-κB and AP-1 to the IL-8 promoter . Another therapeutic feature is that 
MRS2481 is an effective inhibitor of TNF-ǂ, which leads to suppression of phosphorylation 
and proteosomal destruction of IκBǂ (Figure 1). In this way, IκBǂ is maintained and keeps 
the IL-8 promoter silent [85]. Another pharmaceutical strategy against the inflammatory 
phenotype of the CF lung is Parthenolide, which is sesquiterpene lactone derived from the 
feverfew plant. Numerous researchers have controversially proposed that this compound 
suppresses the NF-κB pathway by attenuation of IκBǂ degradation. As we show in Figure 1, 
parthenolide inhibits IκB kinase, ensuring the stabilization of IκBǂ in cytoplasm, hence 
causing inhibition of NF-κB translocation and reduction of following inflammatory 
responses, so parthenolide can be an effective treatment for the excessive inflammation in 
CF [86]. 
another therapeutic medicine, Azithromycin (AZM), has been shown to modulate airway 
inflammation in CF subjects. AZM suppressed IL-8 expression in a CF cell line. Because the 
IL-8 gene is transcripted by NF-κB, it can be concluded that this is the probable pathway by 
which AZM activates NF-κB in the cell line. Such findings indicate the anti-inflammatory 
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task of this macrolide. Suppression of NF-κB activity reveals other proinflammatory 
molecules regulated by this factor as an AZM effect relevant to the treatment of CF [87].  
1.5 Acute respiratory distress syndrome 
Acute respiratory distress syndrome (ARDS) is known for enormous infiltration of 
neutrophils into the lungs accompanied by leak of serum proteins, especially albumin, into 
the alveolar space, blood loss in the intra-alveolar space, and interstitial edema, all 
important and frequent signs in exacerbation of ARDS. In spite of the occurrence of ARDS in 
all over the world, the precise pathophysiology mechanisms remain to be detailed [88]. 
Varying expression levels of proinflammatory cytokines are associated with the progression 
of ARDS. overexperssion of proinflammatory cytokines such as TNF-ǂ, IL-6 and IL-8 in the 
lung has been demontrated in bronchoalveolar lavage (BAL) of ARDS patients and is 
correlated with poor outcome [88]. 
Patients with proved ARDS revealed increased activation of NF-κB in alveolar 
macrophages, in comparison with control subjects without acute lung injury [73]. Because 
there were no notable increases in the levels of transcription factors, including CREB, AP-I , 
or SP- I activation, in alveolar macrophages from patients with ARDS, NF-κB is suggested to 
be a significant upstream regulator for cytokine gene expression in ARDS patients, because 
of its existence on the enhancer of proinflammatory cytokines (Table 1). The level of 
subunits p50, p65, and c- Rel decreased in cytoplasm of alveolar macrophages in ARDS 
subjects, proving the existence of an ongoing stimulus for NF-κB activation. Increased levels 
of oxygen radicals, proinflarnmatory cytokines, and endotoxin in ARDS might be associated 
with NF-κB activation. TNF-a and IL-8 are increased in BAL of ARDS subjects [88]. 
NF-κB activation can alsobe caused by oxygen radicals. Our in vivo data from a 
hemorrhage-induced murine model of ARDS indicates an outstanding role for xanthine 
oxidase, a kind of oxygen radical, in stimulation of NF-κB in lung cells [88]. Cytoplasmic 
and nuclear levels of IκBa are not notibly dissimilar in alveolar macrophages from ARDS 
subjects and controls, so these findings are rather unexpected, because signals that cause 
activation of  NF-κB would be expected to generate phosphorylation. Alveolar macrophages 
have a significant protective role in mediating NF-κB activation in the lung and in initiation 
of neutrophilic inflammation [73, 88]. 
2. Inhalation of some agents cause activation of the NF-κB inflammatory 
pathway in the lung 
Asbestos 
Asbestos belongs to a group of physically occurring, hydrated mineral silicate fibers that are 
causally related to the progression of pulmonary diseases [88]. Iron, which exists in asbestos 
fibers, cause cellular redox changes by generation of intracellular reactive oxygen species, 
leading to activation of NF-κB. It has been shown that, after inhalation of crocidolite and 
chrysotile asbestos, nuclear translocation of RelA increases in rat airway epithelial cells 
(Table 1). The main reason is that macrophages phagocytize asbestos but cannot ‘‘digest’’ 
these fibers. Because the asbestos harms them, these macrophages secret TNF-ǂ, and this 
cytokine mediates activation of NF-κB [73, 89-92].  
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Table 1. The implication of NF-κB in inflamatory lung disease. 
2.1 Sulphur mustard Inhalation 
Sulphur mustard (SM) is a chemical weapon used during the Iraq war against Iran of the 
late 1980s [93, 94]. It can produce damage in skin, eyes, and, , most importantly, in lung. 2-
Chloroethyl ethyl sulphide (CEES) is a sulphur vesicating agent and an analogue of SM. 
Both of these agents are alkylating agents that affect cellular thiols and are highly toxic. 
CEES appears to decrease iNOS expression by associating with the LPS-induced stimulation 
of transcription factor NF-κB. CEES also alkylates the NF-κB consensus sequence, thus 
suppressing the binding of the NF-kB to the iNOS promoter. Even though the activation of 
NF-κB due to SM or CEES countering has been elucidated in different cell lines, the exact 
mechanism of this pathway is still poorly understood, and the question of whether activated 
NF-κB induces an inflammatory pathway remains to be elucidated [95]. 
2.2 Diesel exhaust 
Diesel exhaust (DE) is a major pollutant;exposure increases a prominent inflammatory 
response in the airways, with induction of cytokines such as IL-8, IL-13 and activation of 
redox sensitive nuclear factors (NF-κB, AP-1) in the bronchial epithelium, including 
upregulation in the transcription of ICAM-1 and vascular endothelial adhesion molecules 
(VCAM-1). It has been established that DE activates the p38 and JNK MAPK pathways and 
causes the activation of NF-κB and AP-1 [96]. 
3. Strategies to block NF-κB activation 
Several strategies have been proposed to block the activation of NF-κB. An extensive 
diversity of molecules (both natural and synthetic) has been highlighted as having an effect 
on activation of NF-κB and being able suppress it. These compounds suppress NF-κB 
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activation through various pathways by blocking NF-κB activation. Subsequent information 
has provided strategies for suppressing NF-κB activation in response to different type of 
stimuli. Both steroids and nonsteroidal anti-inflammatory agents are helpful (Table 2). 
Hence, it is important to get a better understanding of the activation of NF-κB and release of 
prostaglandins [64]. Glucocorticoids, including dexamethasone and prednisone, are 
commonly prescribed for their anti-inflammatory and immunosuppressive effects [97-99]. 
These components interact with the steroid receptor and cause reduction of the expression 
of particular genes that control the inflammatory procedure. NF-κB can be inhibited via 
glucocorticoids in different ways. Dexamethasone induces the expression of IκBǂ, which 
causes retention of NF-κB in the cytoplasm, especially of p65. Synthesis of IκBǂ by 
dexamethasone is likely to be dependent on p65 in pre-existing NF-κB complexes. These 
findings show that quick degradation of IκBǂ may be blocked by consequent expression of 
IκBǂ following dexamethasone treatment. Another pathway implicated in glucocorticoid-
mediated repression of the NF-κB is that dexamethasone may inhibit the expression and 
p65-dependent transactivation in endothelial fibroblasts in murine models, but it does not 
have any effect on the IκB level. In the same way, dexamethasone alters NF-κB–mediated 
transcriptional activity in endothelial cells, but it does not alter IκB levels either [64]. 
 
Table 2. Therapeutic agents and drugs which block NF-κB activation. 
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Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively applied to improve the 
therapeutic status of chronic inflammatory states. The most widely hypothesis for the 
inhibitory property of these compounds on the inflammatory response supposes that 
NSAIDs inhibit COX activity to suppress prostaglandin synthesis [64]. 
NSAIDs such as Aspirin and sodium salicylate correlate with NF-κB inhibition. At 
concentrations measured in the serum of patients treated with these drugs for chronic 
inflammatory situations, both aspirin and salicylate suppress NF-κB activation, and aspirin 
has been demonstrated to inhibit the activation of the IκB kinase complex [97, 100]. In 
particular, Aspirin and sodium salicylate prevent NF-κB nuclear translocation by blocking 
IkBǂ phosphorylation and degradation (Figure 1) [3, 100]. These drugs also inhibit TNF-ǂ-
induced mRNA transcription of adhesion molecules such as ICAM-1 in endothelial cells. 
Penetration of neutrophils from endothelial cells can be prevented following NF-κB 
inhibition in these cells. Recently, Yin et al. have reported that Aspirin can bind to and 
prevent the kinase activity of IKKǃ by decreasing its capacity to bind ATP. Other NSADs, 
such as tepoxaline, defereoxamine, and ibuprofen, are also capable of suppressing NF-κB 
activity [100]. 
An aminosalicylate derivative with anti-inflammatory aspects, mesalamine, prevents IL-1–
mediated activation of p65 phosphorylation without suppressing IκBǂ degradation [64]. 
Indomethacin, is another NSAID, is able to inhibit inflammatory responses via suppressing 
COX activity, but it does not prevent activation of the NF-κB pathway [64]. Sulindac is 
illustrated in Figure 1 as a NSAID that is structurally correlated with indomethacin and can 
inhibit activation of the NF-kB pathway by suppressing IKK activity [64, 97].  
These findings suggest that inhibition of the NF-κB pathway might be implicated in the anti-
inflammatory pathways as well as participation of NSAIDs in growth inhibitory properties. 
4. Conclusion 
NF-κB is one of the most important transcription factors and has an important role in 
inflammatory special lung disease [6]. The exact pathophysiological mechanism of NF-κB  
that leads to inflammation continues to be better understood. Pharmacologic therapy used 
for blocking this molecule can be useful for treatment of lung disease. The major 
recommendation for further research is to define the exact molecular mechanisms of each 
inflammatory lung disease that involves NF-κB. This is critical because the glucocorticoids 
which benefit patients with asthma do not work for COPD. Future research will to elucidate 
new methods of treatment for those patients [101].  
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